iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

ITOS Stock  USD 7.81  0.02  0.26%   
Slightly above 61% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 -- iTeos Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug dostarlimab doublet versus placebo pembrolizumab in patients with previously untreated, unresectable, locally ad

Read at finance.yahoo.com
Yahoo News
  

Iteos Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Iteos Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Iteos Therapeutics Maximum Pain Price Across January 17th 2025 Option Contracts

Iteos Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Iteos Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Iteos Therapeutics' options.

Iteos Therapeutics Fundamental Analysis

We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Iteos Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Iteos Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.

Peers

Iteos Therapeutics Related Equities

SANASana Biotechnology   160.61   
0%
100.0%
ERASErasca   3.00   
0%
1.0%
RVMDRevolution Medicines   0.20   
0%
1.0%
KYMRKymera Therapeutics   0.98   
1.0%
0%
DAWNDay One   1.61   
1.0%
0%
AMLXAmylyx Pharmaceuticals   1.82   
1.0%
0%
BPMCBlueprint Medicines   3.96   
2.0%
0%
MLTXMoonLake Immunotherapeuti   4.06   
2.0%
0%
ANNXAnnexon   4.16   
2.0%
0%
APLSApellis Pharmaceuticals   4.71   
2.0%
0%
TCRXTscan Therapeutics   5.32   
3.0%
0%
TERNTerns Pharmaceuticals   6.75   
4.0%
0%
ABOSAcumen Pharmaceuticals   7.10   
4.0%
0%
GLUEMonte Rosa   8.27   
5.0%
0%
DSGNDesign Therapeutics   14.19   
8.0%
0%

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.